A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Clinical trial NCT06908304 · RECRUITING

Trial details

NCT number: NCT06908304
Sponsor: Maia Biotechnology
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small -Cell Lung

Start date: 2025-12-08
Primary completion: 2027-07-31
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.